June 4, 2017
Please join us in congratulating Drs. Matthew Greenblatt and David Rickman, who were each awarded drug discovery grants from the Tri-Institutional Therapeutics Discovery Institute (TDI) in partnership with the Takeda Pharmaceutical Company. The TDI is focused on supporting Tri-I investigators with novel compounds or biologics that have great therapeutic potential.
Dr. Greenblatt received a TDI grant for Development of an Antibody Inhibitor of SLITRK5 for the Treatment of Osteoporosis
Dr. Rickman received a TDI grant for Identification of Novel Therapeutics for Treatment of N-MYC Driven Castrate Resistant Prostate Cancer.
Congratulations, Drs. Greenblatt and Rickman!